Citi Starts Halozyme Therapeutics (HALO) at Buy
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $108.17 +1.93%
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
15 Buy, 5 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Citi initiated coverage on Halozyme Therapeutics (NASDAQ: HALO) with a Buy rating and a price target of $25.00.
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $15.64 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Starts Rio Tinto (RIO) at Underweight
- TD Cowen Assumes Maze Therapeutics (MAZE) at Buy
- Citigroup set to join top banks in Anthropic IPO - Bloomberg
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
